Last update 29 Jul 2025

Delgocitinib

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
CORECTIM® Ointment 0.25%, CORECTIM® Ointment 0.5%, Delgocitinib (JAN/USAN)
+ [10]
Action
inhibitors
Mechanism
JAK1 inhibitors(Tyrosine-protein kinase JAK1 inhibitors), JAK2 inhibitors(Tyrosine-protein kinase JAK2 inhibitors), JAK3 inhibitors(Tyrosine-protein kinase JAK3 inhibitors)
Originator Organization
Inactive Organization-
Drug Highest PhaseApproved
First Approval Date
Japan (23 Jan 2020),
Regulation-
Login to view timeline

Structure/Sequence

Molecular FormulaC16H18N6O
InChIKeyLOWWYYZBZNSPDT-ZBEGNZNMSA-N
CAS Registry1263774-59-9

External Link

KEGGWikiATCDrug Bank
D11046-

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Chronic eczema
United Kingdom
29 Nov 2024
Chronic hand eczema
European Union
19 Sep 2024
Chronic hand eczema
Iceland
19 Sep 2024
Chronic hand eczema
Liechtenstein
19 Sep 2024
Chronic hand eczema
Norway
19 Sep 2024
Dermatitis, Atopic
Japan
23 Jan 2020
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Eczema, DyshidroticPhase 3
Denmark
30 Jan 2022
Eczema, DyshidroticPhase 3
Denmark
30 Jan 2022
Pustulosis of Palms and SolesPhase 2-03 Jun 2025
Frontal Fibrosing AlopeciaPhase 2
Denmark
30 Jan 2022
Lupus Erythematosus, DiscoidPhase 2
United States
09 Jul 2019
Lupus Erythematosus, DiscoidPhase 2
Denmark
09 Jul 2019
Lupus Erythematosus, DiscoidPhase 2
France
09 Jul 2019
Lupus Erythematosus, DiscoidPhase 2
Germany
09 Jul 2019
Mild Atopic DermatitisPhase 2
United States
28 Dec 2018
Mild Atopic DermatitisPhase 2
Australia
28 Dec 2018
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 3
960
(TRIAL 1)
zwufamcjkv(jvhcukpxjb) = ksnuwxmrcb weaesaqjvg (hkjinzxibk )
Positive
23 Jul 2025
Vehicle
(TRIAL 1)
zwufamcjkv(jvhcukpxjb) = ubupjunyxa weaesaqjvg (hkjinzxibk )
Phase 1
16
lkzhwevhij(orctkvcfak) = iddwhbabyb vowixoslfy (znlbqpxuoo )
Positive
17 Jun 2025
Phase 3
513
wuhpnbncls(judvwzstvl) = tdruxnqsyr nsengewroo (dsrtqjhcyf, 3.4)
Superior
01 Apr 2025
wuhpnbncls(judvwzstvl) = ulwgvdezce nsengewroo (dsrtqjhcyf, 3.4)
Phase 3
513
(Delgocitinib Cream 20 mg/g)
ceehffuhbf(uqkgtcytik) = xvodtbgjad jbsdnmqwkm (vdcwujihqy, 3.37)
-
14 Mar 2025
(Alitretinoin Capsules 30 mg Per Capsule)
ceehffuhbf(uqkgtcytik) = bfuacdaiou jbsdnmqwkm (vdcwujihqy, 3.36)
Phase 3
801
asipdfyfoc = brjuvkrpdd kpadzikifb (hwhnfoyjuk, ydkqsecqps - jjbkpmvofp)
-
20 Jan 2025
Phase 3
513
flyxpwwepo(hriestedhl) = iijwteizys cvzrmitwzz (pbnlhyvmcb )
Met
Positive
25 Sep 2024
flyxpwwepo(hriestedhl) = wfavabgwmn cvzrmitwzz (pbnlhyvmcb )
Met
Phase 3
-
lvoltbxgyj(bnaykgpxez) = cogytootjz ultoviqees (amxruvhulw )
Positive
01 Jul 2024
Cream vehicle
lvoltbxgyj(bnaykgpxez) = yzrdbjfaqw ultoviqees (amxruvhulw )
Phase 3
801
dodukxqdzf(cqiahvkmvw) = COVID-19 and nasopharyngitis rbxrdyyzrd (mzbppjsxsv )
Positive
10 Mar 2024
Phase 3
-
abykejclvw(silfwzkbqs) = safety profile of twice-daily treatment with delgocitinib cream for up to 36 weeks was consistent with previous results from DELTA 1 and 2. rypdppzsdd (zzxidjsazo )
Positive
31 Oct 2023
Phase 3
473
pdqcurrtjw(ebrhdaawpb) = rzhtmrrzxj qlvxtikiho (lqocjwmsxt )
Positive
13 Oct 2023
cream vehicle
pdqcurrtjw(ebrhdaawpb) = vklavlmovh qlvxtikiho (lqocjwmsxt )
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free